The melanocortin-4 receptor (MC4R) is a G-protein-coupled receptor expressed in the hypothalamus that sits at the center of the brain's hunger and energy-balance circuit. Activation of MC4R by alpha-MSH (a cleavage product of POMC) suppresses appetite and increases energy expenditure; defects anywhere along the leptin-POMC-MSH-MC4R axis produce severe, often early-onset obesity that does not respond to lifestyle change.
MC4R is one of the most genetically validated obesity targets known. Loss-of-function MC4R mutations are the single most common monogenic cause of obesity, with heterozygous variants present in approximately 1-5% of severe-obesity populations. Targeted pharmacology took years to develop because the receptor's complexity made selective activation difficult without cardiovascular side effects. The first approved MC4R-pathway drug, Rhythm Pharmaceuticals' setmelanotide (IMCIVREE), is a cyclic peptide agonist approved for POMC, PCSK1, and LEPR deficiency obesity (2020), Bardet-Biedl Syndrome (2022), and acquired hypothalamic obesity (March 2026). Bivamelagon is Rhythm's next-generation MC4R agonist now in Phase 3.
MC4R is also a target outside rare disease. The pathway interacts with the GLP-1 and amylin signaling systems that drive the obesity-drug field, and questions about whether MC4R activation can be safely paired with incretin therapy remain active research areas. At ENDO 2026, Rhythm presented seven setmelanotide abstracts spanning three rare-disease indications, reinforcing the case for broader MC4R-pathway Phase 3 development.
Stories here cover MC4R-targeted drug programs and the rare-disease obesity field. See [[setmelanotide]], [[rhythm-pharmaceuticals]], and [[hypothalamic-obesity]] for adjacent threads.
Rhythm Pharmaceuticals (Nasdaq: RYTM) presented seven setmelanotide abstracts at ENDO 2026 covering three rare-disease patient populations. Christian Roth (Seattle Children's) reported 2.5-year Phase 2 + long-term extension data in acquired hypothalamic obesity showing -18.9% mean BMI reduction across all 11 participants. The PWS interim Phase 2 (June 13) reported across 17 patients (10 adult, 7 pediatric) showed 3.11% mean BMI reduction in adults and 3.00% in pediatric patients, with 8 of 10 baseline-hyperphagic patients hitting a 7-point HQ-CT reduction, and 4.19% fat-mass loss with 0.74% lean-mass gain across 16 DEXA evaluations. Two BBS late-breaking posters from Caroline Huber covered real-world hyperphagia and healthcare-utilization outcomes from the 6-month RESTORE study. All three indications reinforce the MC4R-agonist rationale for Phase 3.
A study in the International Journal of Obesity compared semaglutide, tirzepatide, and retatrutide in MC4R-knockout mice, a model of the most common monogenic obesity. Over 21 days, mean body-weight reduction reached 31.6% with tirzepatide, 24.1% with retatrutide, and 19.7% with semaglutide, and tirzepatide also suppressed cumulative food intake most aggressively. All three improved plasma insulin, HOMA-IR, cholesterol, and liver-damage markers, suggesting incretin drugs can drive weight loss even when the POMC-MC4R satiety axis is disrupted.
Rhythm Pharmaceuticals reported Q1 2026 results May 5: setmelanotide (IMCIVREE) net product revenue of $60.1M, up from $37.7M a year earlier ($36.9M US, $23.2M ex-US), driven by 150+ new US start forms in acquired hypothalamic obesity following the FDA approval and the EU Marketing Authorization for the same indication; Japan's PMDA accepted the NDA for review. The MC4R-agonist peptide is the only commercial therapy for hypothalamic obesity. Offsetting the topline beat: the Phase 3 EMANATE trial in genetically caused MC4R-pathway diseases failed its primary endpoint in all four independent substudies, narrowing the indication-expansion runway. Net loss was $56.7M; cash $340.6M for 24+ months runway.